Welcome to our dedicated page for Elanco Animal Health SEC filings (Ticker: ELAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Elanco Animal Health's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Elanco Animal Health's regulatory disclosures and financial reporting.
Elanco Animal Health Inc. reported that a board director received an annual equity grant in the form of deferred stock units. On 11/28/2025, the director acquired 10,314 shares of common stock-equivalent deferred units at a stated price of $0 as an equity award for non-employee members of the Board of Directors. Following this grant, the director beneficially owns 84,813 shares of Elanco common stock in direct form. These awards align the director’s compensation more closely with long-term shareholder value through stock-based incentives.
Elanco Animal Health director reports equity grant
A director of Elanco Animal Health Inc. reported receiving an annual equity award in the form of deferred stock units. On 11/28/2025, the director acquired 10,314 shares of common stock at a reported price of $0, reflecting that this was an equity grant rather than an open‑market purchase. Following this transaction, the director beneficially owned 91,278 shares of Elanco common stock in direct ownership. The award is described as part of the regular annual equity compensation for non‑employee members of the company’s Board of Directors.
Elanco Animal Health Inc. (ELAN) reported an insider equity award for a member of its Board of Directors. On 11/28/2025, director Michael J. Harrington received 10,314 shares of common stock, recorded at a price of $0 per share, reflecting a grant rather than a market purchase. Following this transaction, he beneficially owned 109,577 shares of Elanco common stock in direct ownership. The company explains that this grant represents deferred stock units issued as an annual equity award to each non-employee member of the Board of Directors, aligning director compensation with shareholder interests through stock-based incentives.
Elanco Animal Health Inc. (ELAN) reported a Form 4 filing for executive officer Rajeev A. Modi, Executive Vice President U.S. Pet Health and Global Digital Transformation. On 11/14/2025, he acquired 67.0754 deferred stock units at a price of $21.09 per unit. Following this transaction, he beneficially owns 7,230.2452 deferred stock units, held directly.
Each deferred stock unit represents the right to receive either one share of Elanco common stock or the cash equivalent. According to the company’s Executive Deferral and Stock Match Plan, these deferred stock units will settle in cash or shares after employment ends or in a specified future year.
Elanco Animal Health Inc. executive Jeffrey N. Simmons, the company’s President, CEO and Director, reported a new equity-related award. On 11/14/2025, he acquired 131.3058 deferred stock units at a reference price of $21.09 per unit. After this transaction, he beneficially owned 18,355.9214 derivative securities, held directly. Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent, and these units are designed to settle in cash or shares following termination of employment or during a specified future year under the Executive Deferral and Stock Match Plan.
T. Rowe Price Investment Management, Inc. filed a Schedule 13G reporting beneficial ownership of 31,547,970 shares (6.4%) of Elanco Animal Health common stock as of 09/30/2025.
The filer reports sole voting power over 31,482,581 shares and sole dispositive power over 31,547,970 shares, with no shared voting or dispositive power. It certifies the holdings were acquired and are held in the ordinary course and not for the purpose of changing or influencing control.
Elanco Animal Health (ELAN) filed its Q3 2025 10‑Q, reporting revenue of $1,137 million, up from $1,030 million a year ago. Gross profit was $607 million. The quarter showed a net loss of $34 million (basic and diluted EPS of $(0.07)), compared to a prior-year period boosted by a $640 million gain on an asset sale. Year-to-date net income was $44 million.
Pet Health revenue was $533 million and Farm Animal totaled $593 million. Operating cash flow for the first nine months reached $452 million. Cash was $505 million, and long‑term debt (excluding finance lease) was $3,769 million, down from $4,321 million at year‑end. In May, Elanco monetized certain future XDEMVY royalties for $295 million, recorded as a $300 million liability with a 16.2% effective interest rate. Subsequent to quarter‑end, the company refinanced debt with new facilities and fully repaid its prior Term Loan B; the weighted‑average effective interest rate decreased to 5.77% as of October 31, 2025. Shares outstanding were 496,863,473 as of October 31, 2025.
Elanco Animal Health (ELAN) furnished a Current Report announcing results for the fiscal quarter ended September 30, 2025, along with guidance for the full year and fourth quarter of 2025. The details are provided in a press release attached as Exhibit 99.1, dated November 5, 2025.
The Item 2.02 information, including Exhibit 99.1, was furnished and is not deemed filed under the Exchange Act.
Elanco Animal Health (ELAN) reported that President, CEO and Director Jeffrey N. Simmons acquired 125.0221 deferred stock units on 10/31/2025 at $22.15 per unit. Following this transaction, he beneficially owns 18,224.6156 derivative securities, held as direct ownership.
Each deferred stock unit represents the right to receive one share of common stock or the cash equivalent. These units settle in cash or shares following termination of employment or during a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health (ELAN) officer Rajeev A. Modi reported a routine insider transaction on a Form 4. On 10/31/2025, he acquired 63.8655 Deferred Stock Units (DSUs) in a transaction coded “A.” Following this activity, he beneficially owned 7,163.1698 derivative securities, held directly. The filing lists a $22.15 price for the derivative security. Each DSU represents the right to receive one share of Elanco common stock or the cash equivalent, and DSUs settle in cash or shares following termination of employment or during a specified future year in accordance with the Executive Deferral and Stock Match Plan.